Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can your own blood help stop leakage? a new trial investigates

NCT ID NCT07807982

Disease control Sponsor: Benha University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This trial tests whether injecting platelet-rich plasma (PRP) around the urethra can safely reduce stress urinary incontinence in postmenopausal women. PRP is made from each participant's own blood and contains growth factors that may help repair tissue. About 70 women will receive monthly injections for four months, and researchers will track changes in leakage, urinary symptoms, and side effects. The goal is to see if this minimally invasive approach offers a viable alternative for women who are not candidates for surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Autologous platelet-rich plasma (PRP) injected around the urethra
What this could lead to
If it works, this could offer a minimally invasive treatment option for postmenopausal women with stress urinary incontinence who cannot have surgery.
What could go wrong
This is a small, early-stage study, and PRP's effectiveness for this condition is not yet proven. Possible risks include injection-related discomfort, infection, or no improvement in symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Postmenopausal women aged 45 years or older. * Stress urinary incontinence confirmed by urodynamic study with intrinsic sphincter deficiency. * Persistent stress urinary incontinence requiring pad use despite conservative management. * Patients unfit for surgical intervention and anesthesia. * Coagulation disorders or current anticoagulant therapy that cannot be safely discontinued. * Patients with comorbidities. Exclusion Criteria: * Urinary tract infection. * Neurological disorders affecting lower urinary tract function. * Pelvic organ prolapse greater than stage II according to the Pelvic Organ Prolapse Quantification system. * Previous urethral surgery. * Inability or unwillingness to comply with follow-up visits.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stress urinary incontinence are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

female stress incontinence Urinary Incontinence Urinary Incontinence, Stress

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stress urinary incontinence

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Benha University Hospital

    Banhā, Qalyubia Governorate, 13511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.